Huang W, Chen Y, Wang N, Yin G, Wei C, Xu W, et al.
Journal of diabetes research. Date of publication 2020 Feb 1;volume 2020():6245758.
1. J Diabetes Res. 2020 Feb 1;2020:6245758. doi: 10.1155/2020/6245758.
eCollection 2020.
The Efficacy and Safety of Acellular Matrix Therapy for Diabetic Foot Ulcers: A
Meta-Analysis of Randomized Clinical Trials.
Huang W(1)(2), Chen Y(1), Wang N(1), Yin G(1), Wei C(3), Xu W(1).
Author information:
(1)Department of Endocrinology and Metabolism, The First Affiliated Hospital of
Shantou University Medical College, 57 Changping Road, Shantou 515041, China.
(2)Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
(3)Multidisciplinary Research Center, Shantou University, 243 Daxue Road,
Shantou 515063, China.
BACKGROUND: Acellular matrix (AM) therapy has shown promise in the treatment of
diabetic foot ulcers (DFUs) in several studies. The clinical effects of AM
therapy were not well established. Therefore, we conducted a meta-analysis of
randomized clinical trials (RCTs) to examine the efficacy and safety of AM
therapy for patients with DFUs.
METHODS: A literature search of 5 databases was performed to identify RCTs
comparing AM therapy to standard therapy (ST) in patients with DFUs. The primary
outcome was the complete healing rate and the secondary outcomes mainly included
time to complete healing and adverse events.
RESULTS: Nine RCTs involving 897 patients were included. Compared with ST group,
patients allocated to AM group had a higher complete healing rate both at 12
weeks (risk ratio (RR) = 1.73, 95% confidence interval (CI): 1.31 to 2.30) and
16 weeks (RR = 1.56, 95% CI: 1.28 to 1.91), a shorter time to complete healing
(mean difference (MD) = -2.41; 95% CI: -3.49 to -1.32), and fewer adverse events
(RR = 0.64, 95% CI: 0.44 to 0.93).
CONCLUSION: The present study suggests that AM therapy as an adjuvant treatment
could further promote the healing of full-thickness, noninfected, and
nonischemia DFUs. AM therapy also has a safety profile. More large well-designed
randomized clinical trials with long follow-up duration are needed to further
explore the efficacy and safety of AM therapy for DFUs.
Copyright © 2020 Wentao Huang et al.
DOI: 10.1155/2020/6245758
PMCID: PMC7016477
PMID: 32090122 [Indexed for MEDLINE]
Conflict of interest statement: The authors declare that there is no conflict of
interest regarding the publication of this paper.
